Objective: Sympathetic nervous system (SNS) overactivity is a risk factor for insulin resistance and cardiovascular disease (CVD). We evaluated the impact of bromocriptine-QR, a dopamine-agonist antidiabetes medication, on elevated resting heart rate (RHR) (a marker of SNS overactivity in metabolic syndrome), blood pressure (BP) and the relationship between bromocriptine-QR's effects on RHR and HbA1c in type 2 diabetes subjects.
| INTRODUC TI ON
The sympathetic nervous system (SNS) plays an important role in maintaining normal cardiovascular homeostasis and health by regulating systemic vascular resistance, blood pressure (BP), heart rate, cardiac output and normal vascular endothelial function in response to a multitude of acute environmental, physical and mental status alterations. 1, 2 It also regulates normal glucose homeostasis by enhancing hepatic glucose output and adipose-free fatty acid mobilization during fasting periods of the day and in circumstances such as acute hypoglycaemia or prolonged starvation. [3] [4] [5] [6] [7] [8] However, chronic overactivity of the SNS leads to cardiovascular as well as metabolic adverse effects. [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] Cardiovascular adverse effects of chronically elevated sympathetic tone include vasoconstriction facilitating increased BP, an overactivated renin-angiotensin system potentiating increased BP, increased heart rate and most importantly inflammation and reactive oxygen species (ROS) generation in the micro-and macro-vasculature as well as within the myocardium itself potentiating arterial stiffness, myocardial apoptosis and myocardial ischaemia/reperfusion injury. 2, 10, [15] [16] [17] [18] [19] [20] [21] [22] [23] Less well recognized are the adverse metabolic effects of chronically increased SNS activity, which include increased hepatic gluconeogenesis, decreased hepatic glucose disposal, increased free fatty acid (FFA) mobilization from the adipose tissue, ROS generation and inflammation in adipose and liver, and decreased blood flow to muscle, all potentiating insulin resistance in those tissues and beta cell dysfunction resulting from inflammatory factors, ROS, lipotoxicity and glucotoxicity. 10, 12, 13, 16, 18, [24] [25] [26] Elevated resting heart rate (RHR) can reflect elevated central sympathetic-to-parasympathetic activity balance 27, 28 and has been shown to be a common occurrence in insulin resistance syndrome, independent of high BP or obesity. [29] [30] [31] [32] Most importantly, in the insulin resistance syndrome, elevated RHR values are significantly correlated with other measures of SNS activity such as muscle sympathetic nerve activity and serum noradrenaline levels. 12, 16, 18, 29 While clinically RHR between 60 and 100 beats per minute (BPM) is considered the "normal" range for RHR and RHR ≥100 is used as the criteria for defining tachycardia, a large body of evidence from epidemiological and clinical studies suggests that increasing RHR within the "normal" range is associated with increased cardiometabolic risk, particularly above 70-80 beats per minute (BPM). Such elevated RHR has been associated with insulin resistance, 26, 33 altered beta cell function, 34 impaired glucose regulation and increased risk of developing type 2 diabetes mellitus [35] [36] [37] as well as increased cardiovascular disease (CVD) risk [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] and mortality. [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] 51, 52, 54, [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] Bromocriptine-QR (B-QR), a quick-release formulation of micronized bromocriptine, is the only sympatholytic dopamine-agonist US FDA-approved for the treatment of type 2 diabetes. In several preclinical [66] [67] [68] [69] [70] [71] [72] and clinical studies, [73] [74] [75] [76] [77] [78] [79] [80] [81] [82] [83] [84] The biological clock pacemaker circuit (circadian efferent signals to and including the SCN) for the body is a primary regulator of autonomic balance in the body. [85] [86] [87] A diminution of the circadian peak in dopaminergic input signalling to this SCN clock system (at daily waking from the sleep cycle) is coupled to and potentiates an increase in hypothalamic pre-autonomic neuronal activities that lead to overactivation of the SNS and metabolic syndrome in animals. 88 The circadian-timed administration of either dopamine agonist systemically or dopamine to the SCN clock area in insulin-resistant animals to induce (mimic) the normal circadian peak of dopaminergic activity at the SCN pacemaker that is diminished in insulin resistance states has been observed to reduce chronic overactivity of SNS pre-autonomic neurons in the hypothalamus and measures of subsequent chronic activation of peripheral sympathetic tone in insulin-resistant states. 66, [88] [89] [90] [91] [92] [93] Moreover, reduction of brain dopamine synthesis in healthy humans for just a couple of days induces peripheral insulin resistance. 94, 95 Circadian-timed (onset of daily waking) administration of the antidiabetes agent B-QR, a quick-release formulation of micronized bromocriptine, to re-establish the normal circadian peak of central nervous system (CNS) dopaminergic activity that is diminished in insulin-resistant states among mammals has been observed to improve insulin sensitivity and reduce CVD events in type 2 diabetes. 96, 97 Therefore, the possibility exists that such B-QR therapy may reduce elevated RHR, a measure of SNS tone in insulin resistance syndrome, 29 that may in part explain the agent's impact to improve glycaemic control 96 and reduce adverse cardiovascular outcomes in type 2 diabetes. [98] [99] [100] [101] However, the impact of circadian B-QR therapy on the pathophysiological parameter of elevated RHR and, importantly, its relation to glycaemic control in type 2 diabetes has never been investigated. The primary aim of this present study was twofold: (a) to investigate the effect of B-QR on elevated RHR in type 2 diabetes subjects and (b) to assess the nature of any inter-relationship between B-QR's impact to reduce elevated RHR and to reduce HbA1c in these subjects.
| ME THODS

| Study subjects and design
The study population (N = 1014) of type 2 diabetes subjects was derived from the Cycloset Safety Trial (CST). The study protocol and design for the CST have been previously described in detail. 98, 102 Briefly, the CST was a multicenter, placebo-controlled, doubleblind, parallel-group safety and efficacy study in outpatient type 2 diabetes subjects recruited from general practice and diabetes clinics across 74 clinical centres in the United States and Puerto Rico.
Subjects were between the ages of 30 and 80 years and had a body mass index <43 kg/m 2 , with established type 2 diabetes by ADA 2003 criteria and HbA1c ≤10.0%. Subjects with New York Heart Classifications I and II congestive heart failure (CHF) were allowed to participate, as were subjects with a history of myocardial infarction (MI) or coronary revascularization occurring >6 months before enrolment. Subjects were required to have maintained a stable diabetes treatment regimen for ≥30 days prior to randomization, consisting of lifestyle interventions of medical nutrition therapy and appropriately prescribed physical activity with or without oral antihyperglycaemic agents (≤2) or insulin either alone or in combination with 1 oral antihyperglycaemic agent.
Following randomization (2:1 active agent vs placebo), the study drug (B-QR or placebo) was titrated from an initial starting dose of 1 tablet daily (0.8 mg B-QR per tablet or matching placebo) by increasing the daily dose by 1 tablet per week until a maximum tolerated daily dose between 2 and 6 tablets once daily (1.6-4.8 mg B-QR/day) was achieved. The study drug was taken with the morning meal, within 2 hours of waking. Subjects were required to continue their established antihyperglycaemic treatments during the first 3 months of the study. However, the dosages of the oral agents or insulin could be modified as deemed appropriate by the study site investigator. After 3 months, alterations in the diabetes treatment regimen were allowed, if deemed necessary by the study site investigator, as long as these changes did not result in a final regimen that exceeded two oral agents or insulin plus one oral agent, exclusive of the study drug. Due to the above study design, the prespecified statistical analysis plan for the CST 102 had specified that data at 24 weeks of treatment be considered for efficacy analyses and therefore were used to assess B-QR's effects on dysglycemia and RHR in the present study. The study population for the present study consisted of all subjects from the CST who completed 24 weeks of study drug treatment with no concomitant hypertension medication changes (to avoid confounding arising from BP and/or heart rate effects from changes in concomitant antihypertensive medications during this period) and no antidiabetes medication changes (since the original CST protocol had allowed for changes in dosages and regimens of antidiabetes medications, to avoid any potential confounding arising from the possibility of such diabetes medication changes affecting RHR or BP changes). Subjects on insulin therapy were excluded from this population given the limitations of the database in clearly determining insulin dose changes (and hence ensuring that there were no changes in concomitant diabetes therapies) and also more importantly to control for the potential effects of insulin itself and changes in insulin dose on sympathetic activity given that insulin acts centrally to increase SNS activity. 103, 104 A total of 1014 subjects (642 B-QR, 372 placebo) meeting the above criteria constituted the study population for this study.
Resting heart rate was derived from 12-lead electrocardiograms (ECGs) obtained at baseline and at 24 weeks. BP and HbA1c measurements were obtained at the baseline and 24-week study visits. 
| Statistical analyses
| RE SULTS
| Baseline characteristics
The baseline characteristics of the study population are shown in Table 1 . Study subjects in the B-QR and placebo treatment arms were well matched at baseline within each RHR subgroup and overall; besides the expected difference in mean RHR, there were no major differences in the baseline characteristics of subjects across the different RHR subgroups. The average blood pressure control was good in all groups but close to 70% of the subjects had a history of hypertension in each group and were on antihypertensive medications. In this regard, it should be re-emphasized that concomitant antihypertensive medication changes did not occur during the course of this study per the study inclusion criteria described in Section 2.
| RHR threshold for effect of B-QR
Two-way analysis of variance to explore the effect of treatment Table 2 for details). In the baseline baseline RHR <60 or 60-69 (ie RHR <70). Baseline RHR < or ≥70 was therefore used as the cut-off for the subsequent analyses as described below.
| Effects of B-QR on RHR and BP stratified by baseline RHR ≥70/<70
Among subjects with baseline RHR ≥70 (N = 372:243 B-QR, 129 placebo), RHR decreased from baseline to week 24 on average by −4.8 BPM in the B-QR treated group and by −1.5 in the placebotreated group yielding a between-group difference of −3.4 BPM (P = .001) (see Table 3 for more details). B-QR therapy relative to placebo also reduced SBP by −3.6 mm Hg (P = .02), DBP by −1.9 mm Hg (P = .05) and MAP by −2.5 mm Hg (P = .02) (see Table 3 for more details).
Among subjects with RHR <70 at baseline, there was no reduction in RHR within either treatment group and no significant difference in the RHR change from baseline with B-QR therapy relative to placebo (between-treatment group difference in change in RHR from baseline −0.4, P = .5).
Multivariable regression analysis demonstrated that treatment with B-QR (vs placebo) is a significant independent predictor (P = .001) of change in RHR, after adjusting for other factors including age, gender, race, BMI, duration of diabetes, baseline HbA1c, and baseline as well as change in SBP and DBP, in subjects with baseline RHR ≥70 but not in those with baseline RHR <70.
| Effect of baseline HbA1c on B-QR's impact on RHR
The The magnitude of the RHR reductions from baseline with B-QR vs placebo was even greater when the analyses were limited to subjects with elevated baseline RHR ≥80 (N = 124:85 B-QR, 39 placebo), with a mean change in RHR from baseline to week 24 with B-QR therapy vs placebo of −4.5 BPM (P = .07) in those with baseline HbA1c ≤7, −7.8 BPM (P = .015) in those with baseline HbA1c >7 and −9.9 BPM (P = .005) in those with baseline HbA1c ≥7.5 (Figure 1 ; Table 4 ).
There 
| Effect of baseline RHR on B-QR's glycaemic effect
To assess the relationship between baseline RHR and the antidiabe- 
| Relationship between B-QR-induced change in RHR and B-QR's antidiabetes effect
The Table 5 for more details). drive to the cardiovascular system. 66, 73, 74, 76, 84 Importantly, the magnitude of the B-QR effect to reduce elevated RHR increased also with increasing HbA1c level at baseline which may reflect higher levels of underlying elevated sympathetic activity contributing to both the elevated RHR and higher A1c in these subsets. In addition, the degree of B-QR's impact to reduce elevated RHR was an independent predictor of its effect to reduce HbA1c among subjects with poor glycaemic control (baseline HbA1c ≥7.5). To our knowledge, this is the first demonstration of such an effect on RHR with any FDA-approved antidiabetes medication. This interaction suggests that B-QR therapy may be targeting an aetiologic factor of both elevated RHR and dysglycemia. This aetiologic factor likely is elevated SNS activity, an autonomic imbalance pathology known to both increase RHR and potentiate insulin resistance and dysglycemia. 10, 12, 13, 26 Such a SNS target of B-QR would be consistent with the reported sympatholytic mechanism of action of circadian-timed B-QR therapy to improve glycaemic control and reduce CVD risk in type 2 diabetes subjects. 96, 105 However, although SNS innervation of the myocardium is extensive and exerts a prominent control of myocardial function, 106 reduced parasympathetic drive to the heart may also contribute to elevated SNS tone] for) the 40%-50% reduction in CVD outcomes observed with this therapy in the type 2 diabetes population. [98] [99] [100] [101] The observation that (a) the higher the RHR the greater the Importantly, in insulin resistance syndrome, elevated RHR (over 70-80 BPM) is a marker of an increase in cardiac SNS dominance either in absolute terms or in relative terms of SNS/parasympathetic nervous system (PSNS) activity balance 27, 28, 106 and SNS overactivity is considered to be the most likely central mechanism to explain the association between elevated RHR and adverse cardiometabolic outcomes. 12, 18, 26, 37 While the autonomic imbalance of elevated SNS and depressed PSNS activities to the heart each can contribute to elevated RHR, available evidence suggests that the elevated RHR association with insulin resistance syndrome is most closely coupled to overactive SNS tone that involves several metabolic tissues in addition to the heart. 10, 12, [16] [17] [18] [19] 24, 25, 37, 112, 113 Both elevated RHR [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [51] [52] [53] [54] [55] [56] [57] and elevated SNS tone [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] 114 are associated with and predict the future onset of CVD, insulin resistance, metabolic syndrome and type 2 diabetes. The association of elevated RHR with development of type 2 diabetes has been mainly attributed to increased insulin resistance secondary to elevated SNS activity, 12, 16, 26, [35] [36] [37] although elevated RHR has also TA B L E 4 Resting heart rate changes with bromocriptine-QR vs placebo stratified by baseline resting heart rate and baseline haemoglobin A1c
| D ISCUSS I ON
Baseline RHR groups stratified by baseline HbA1c
Bromocriptine-QR (B-QR) Placebo (P) Between-treatment group difference in RHR change
Week 0-24 (P-value) RHR at baseline
RHR change
Week 0-24 RHR at baseline
Week been reported to be a predictor of beta cell dysfunction and consequent impaired glucose regulation independent of the level of insulin sensitivity. 34 Chronic SNS overactivity is an important pathophysiological phenomenon that potentiates hypertension, vasoconstriction and vascular insulin resistance, 20, [115] [116] [117] [118] vascular oxidative stress, 19, 119 endothelial dysfunction, 19, [120] [121] [122] myocardial oxidative and nitrative stress and apoptosis, 15 and renal renin-angiotensin system overactivation, [20] [21] [22] [23] as well as metabolic changes such as increased adipose inflammation and lipolysis 3, 24, 123, 124 (inducing hyperaemia, a potent stimulus for central activation of SNS tone 125, 126 ), increased hepatic oxidative stress, inflammation, lipotoxicity, glucose output, insulin resistance, 66, 127 ectopic fat deposition 24, 66 and muscle insulin resistance. [128] [129] [130] Collectively, these pathophysiologies underlie development of vascular stiffness and arteriosclerosis, atherosclerosis and atherosclerosis progression, cardiac remodelling, occurrence of myocardial ischaemia and arrhythmias, reduced left ventricular function, kidney dysfunction, hypertension and metabolic derangements of obesity, dyslipidemia, metabolic syndrome and type 2 diabetes, [10] [11] [12] [13] 41, 114, 131 occurrences often associated with elevated RHR. [10] [11] [12] [13] 18, 26, 36, 37, 41, 114, 131 Long-term bromocriptine therapy is well known to reduce elevated sympathetic tone in hypertensive animals and humans. [66] [67] [68] [69] [70] [71] [72] [73] [74] [75] [76] [77] [78] [79] [80] [81] [82] [83] [84] 132 The present study extends the specifics of these findings on vascular hemodynamics and uncovers an important TA B L E 5 Relationship of treatmentinduced change in resting heart rate with change in haemoglobin A1c storage processes with wake-feeding periods of the day). The SCN is the seat of the autonomic nervous system, sending direct and indirect signals to multiple CNS (eg, hypothalamic) centres that are pre-autonomic fibres regulating sympathetic/parasympathetic activity balance from moment to moment and rhythmically over the course of the day. [85] [86] [87] [88] [135] [136] [137] A series of studies have demonstrated that a diminution of circadian peak dopaminergic activity at the SCN area signals the SCN to send neural messages to several brain centres to activate sympathetic tone and alter glucose and FFA sensing in a manner that potentiates glucose intolerance, insulin resistance, and leptin resistance. 96 Elements of the western lifestyle including high fat/sugar diets, psychological stress and altered sleep/wake architecture all diminish brain dopamine activity and are strongly associated with insulin resistance syndrome. [138] [139] [140] [141] [142] Reinstatement of the circadian peak in brain dopaminergic activity in insulin resistance syndrome attenuates these brain (SCN) neural signalling pathways that potentiate the syndrome. 96 The limitations of this study include the absence of any additional direct measures of SNS tone, the lack of physical activity/fitness data on the study subjects which may influence RHR and glycaemic control, and the lack of measures of insulin sensitivity to assess correlations between RHR and insulin action. The present findings however suggest that such future studies are warranted.
| CON CLUS ION
The present study has demonstrated that circadian-timed bromocriptine-QR therapy significantly reduces elevated (but not normal) RHR and blood pressure in type 2 diabetes subjects, the magnitude of which RHR reduction is positively correlated to each of the baseline elevated RHR and HbA1c level. This impact of B-QR to reduce elevated RHR is an independent predictor of its impact to reduce elevated HbA1c (ie the greater the RHR reduction, the greater the HbA1c reduction).
These findings lend further support to the reported bromocriptine-QR mechanism of improving glycaemic control in type 2 diabetes in part via reduction of elevated SNS tone. 105 These findings also suggest that type 2 diabetes maximum responder populations to bromocriptine-QR may be those subjects with elevated (>~80 BPM) RHR or other markers of elevated SNS tone. The impact of B-QR to reduce elevated RHR (and the antecedent elevated SNS tone) provides a potential contributing mechanism for the observed marked reduction in CVD outcomes with B-QR therapy. [98] [99] [100] [101] 
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